Onrubia-Márquez, Mónica from e-cienciaDatos Harvested Dataverse published data on mesoporous silica nanoparticles for Parkinson's disease treatment. The dataset likely contains results from in vivo experiments using a 6-hydroxydopamine-induced mouse model, comparing the efficacy of nanoparticle-loaded L-dopa to free L-dopa. It was last updated on 2026-05-31.
Use Cases
- Compare drug efficacy metrics based on behavioral outcomes like spontaneous rotational behavior.
- Analyze controlled-release performance of nanoparticle formulations based on in vitro release data.
- Evaluate the therapeutic potential of drug-structure-directing agents (DSDAs) based on loading capacity and in vivo results.
Strengths
- Dataset is based on a defined murine model of Parkinson's disease induced by unilateral 6-OHDA injection.
- Description provides a clear scientific hypothesis and methodology for comparing two novel MSN formulations against a standard treatment.
- The data supports a specific claim: a single dose of L-dopa-loaded MSNs outperformed free L-dopa in reducing rotational behavior.
Limitations
- Column-level documentation is absent; field semantics must be inferred after download.
- Row count is unknown, which may limit suitability assessment for large-scale statistical analysis.
- The dataset's scope is limited to a specific preclinical model, and its translational applicability to humans is not directly addressed.
Provenance
- Source
- Onrubia-Márquez, Mónica via e-cienciaDatos Harvested Dataverse
- Collection Method
- Likely contains experimental data from in vitro and in vivo studies of nanoparticle drug delivery systems.
- Freshness
- Last updated 2026-05-31 04:10:21; freshness should be verified.